Table 1.
Demographics of the enrolled patients with glioma who underwent genomic profiling test (CGPT). (n = 104).
| Characteristic | Subset |
n Total (Recurrent) |
Median Age (Range) [y] |
|---|---|---|---|
| Gender | male | 63 (15) | 49 (24–91) |
| female | 41 (11) | 59 (22–72) | |
| Genomic Profiling Test | FoundationOne CDx Cancer Genomic Profile | 94 (24) | 49.5 (24–91) |
| OncoGuide NCC OncoPanel System | 10 (2) | 49 (22–72) | |
| Diagnosis (WHO 2021) | Glioblastoma, IDH-wildtype | 49 (12) | 56 (27–91) |
| Diffuse Astrocytoma, IDH-wildtype, NEC | 6 (0) | 49 (37–64) | |
| Astrocytoma, IDH-mutant | |||
| Grade 4 | 8 (5) | 40.5 (31–52) | |
| Grade 3 | 11 (3) | 46 (29–74) | |
| Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted | |||
| Grade 3 | 17 (6) | 46 (29–74) | |
| Grade 2 | 6 (0) | 49 (35–72) | |
| Diffuse midline glioma, H3 K27-altered | 6 (0) | 36.5 (30–45) | |
| Pilocytic astrocytoma | 1 (0) | 22 (NA) |
Histological classification was re-defined based on the 2021 WHO Classification of Tumors of the Central Nervous System (WHO 2021). The text in parentheses describes the number of recurrent cases for each histological classification. IDH: isocitrate dehydrogenase; NEC: not elsewhere classified.